全文获取类型
收费全文 | 2120篇 |
免费 | 154篇 |
国内免费 | 39篇 |
学科分类
医药卫生 | 2313篇 |
出版年
2023年 | 57篇 |
2022年 | 40篇 |
2021年 | 166篇 |
2020年 | 86篇 |
2019年 | 102篇 |
2018年 | 133篇 |
2017年 | 79篇 |
2016年 | 104篇 |
2015年 | 82篇 |
2014年 | 100篇 |
2013年 | 128篇 |
2012年 | 163篇 |
2011年 | 148篇 |
2010年 | 86篇 |
2009年 | 53篇 |
2008年 | 124篇 |
2007年 | 119篇 |
2006年 | 86篇 |
2005年 | 90篇 |
2004年 | 64篇 |
2003年 | 71篇 |
2002年 | 51篇 |
2001年 | 18篇 |
2000年 | 13篇 |
1999年 | 15篇 |
1998年 | 8篇 |
1997年 | 9篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 8篇 |
1992年 | 14篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 7篇 |
1986年 | 3篇 |
1985年 | 7篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1969年 | 3篇 |
1932年 | 1篇 |
排序方式: 共有2313条查询结果,搜索用时 15 毫秒
1.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
2.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献3.
4.
Satoshi Ebata Ayumi Yoshizaki Takemichi Fukasawa Asako Yoshizaki-Ogawa Yoshihide Asano Kosuke Kashiwabara Koji Oba Shinichi Sato 《The Journal of dermatology》2022,49(1):179-183
The benefit of rituximab (RTX) for systemic sclerosis-associated interstitial lung disease (SSc-ILD) has been shown in previous clinical trials. However, predictors of RTX efficacy have not been clarified. We investigated whether B-cell responsiveness to RTX is related to therapeutic effect. Ten SSc-ILD patients treated with RTX in an independent clinical trial (Japan Registry of Clinical Trials, jRCTs031180373) were included in this analysis. Peripheral B-cell counts were examined retrospectively before RTX administration (baseline) and at 2, 4, 12, and 24 weeks after the first RTX administration, along with percent-predicted forced vital capacity (%FVC) before and 24 weeks after RTX treatment. Relative to baseline, the percentage of residual peripheral blood B cells at 2 weeks after RTX was negatively correlated with the %FVC improvement at the 24-week assessment (r = ?0.41, p = 0.04). In the subgroup with less than 5% B-cell persistence at week 2, %FVC at the 24-week assessment was significantly improved compared to baseline (p = 0.02). In another subgroup with more than 5% residual B cells, %FVC was not significantly different after 24 weeks compared to baseline (p = 0.41). In conclusion, the removal rate of B cells after 2 weeks of RTX treatment may be a useful surrogate marker of subsequent SSc-ILD improvement. 相似文献
5.
6.
7.
Kosuke Yoshihara Takayuki Enomoto Daisuke Aoki Yoh Watanabe Junzo Kigawa Nobuhiro Takeshima Hyoe Inomata Kana Hattori Masahisa Jinushi Hitoshi Tsuda Toru Sugiyama 《Cancer science》2020,111(9):3350-3358
Whether germline (g) breast cancer susceptibility gene (BRCA) mutations are located within or outside the ovarian cancer cluster region (OCCR) (1380‐4062 bp for gBRCA1, and between 3249‐5681 bp and 6645‐7471 bp for gBRCA2) may influence risk variations for ovarian cancers. This ad hoc analysis of the CHARLOTTE epidemiological study in Japan assessed the distribution of gBRCA1/2 mutations in patients with newly diagnosed ovarian cancer, and investigated an association between gBRCA1/2 mutation locations and ovarian cancer risk. Differences in patient background and clinical characteristics in subgroups stratified by gBRCA1/2 mutation locations were also evaluated. We analyzed the data of 93 patients (14.7%) from the CHARLOTTE study who were positive for gBRCA1/2 mutations. After excluding 16 cases with L63X founder mutation, 28 (65.1%) of gBRCA1 mutations were within the OCCR. Of 30 gBRCA2 mutations, 15 (50.0%) were within the OCCR. Of 27 patients (one patient excluded for unknown family history) with gBRCA1 mutations located in the OCCR, 11 (40.7%) had a family history of ovarian cancer; the proportion of patients with a family history of ovarian cancer and gBRCA1 mutations outside the OCCR was lower (13.3%). Sixty percent of patients with gBRCA1 mutations outside the OCCR had a family history of breast cancer; the proportion of patients with a family history of breast cancer and gBRCA1 mutations within the OCCR was relatively lower (33.3%). Understanding the mutation locations may contribute to more accurate risk assessments of susceptible individuals and early detection of ovarian cancer among gBRCA mutation carriers. 相似文献
8.
9.
10.